c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial.

Robert D MorganCristina FerrerasIsabel PesetEgle AvizienyteAndrew G RenehanRichard J EdmondsonAlexander D MurphyShibani NicumThomas Van BrusselAndrew R ClampDiether LambrechtsCong ZhouGordon C Jayson

Published in: BMC medicine (2022)

In bevacizumab-treated women diagnosed with EOC, high c-MET/VEGFR-2 co-localisation on tumour tissue and the VEGFR-2 rs2305945 G/G variant, which may be biologically related, were associated with worse survival outcomes.

Keyphrases

vascular endothelial growth factor
tyrosine kinase
metastatic colorectal cancer
polycystic ovary syndrome
clinical trial
study protocol
phase iii
stem cells
metabolic syndrome
free survival
cell therapy